Literature DB >> 20118108

Use of carbohydrate-deficient transferrin (CDT) and a combination of GGT and CDT (GGT-CDT) to assess heavy alcohol consumption in traffic medicine.

Vincenza Bianchi1, Alessandra Ivaldi, Alessia Raspagni, Carlo Arfini, Matteo Vidali.   

Abstract

AIMS: Carbohydrate-deficient transferrin (CDT) has become widely used in traffic medicine to detect chronic alcohol abuse among subjects applying for driving-license renewal or regranting. By defining cut-off values in a large population of abstainers and moderate drinkers, we report on CDT, GGT-CDT (a combination of gamma-glutamylaminotransferase (GGT) and CDT) and the association between blood alcohol concentration (BAC) and CDT among Italian drivers.
METHODS: CDT was evaluated by a high performance liquid chromatography (HPLC)-based commercial kit in 652 abstainers or moderate drinkers, 603 drivers applying for driving-license regranting after a rehabilitation programme and 105 drivers involved in car accidents with blood alcohol concentration higher than the legal limit used in Italy (BAC >0.5g/l). GGT-CDT was calculated according to Sillanaukee and Olsson and Niemelä. BAC has been assessed by gas chromatography-mass spectrometry.
RESULTS: A common CDT cut-off (1.8%) and gender-specific GGT-CDT cut-off (4.15% for males, 3.56% for females) were calculated as 99.9th percentiles of the control population. Also, 3% and 27% of subjects were classified as CDT positive respectively among drivers applying for license regranting and drivers involved in car accidents. A significant association between BAC and both CDT values and CDT positivity was found, with a frequency up to 49% of CDT samples, suggesting chronic alcohol abuse, among drivers with BAC >2.5g/l. Concordance between CDT and GGT-CDT was only moderate (kappa = 0.44), with CDT performing better than GGT-CDT.
CONCLUSIONS: A relevant proportion of drivers with high BAC are chronic abusers. GGT-CDT, previously validated with CDT immunoassays, should not be applied to traffic medicine in its current form and its performances re-evaluated with CDT measured by HPLC.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20118108     DOI: 10.1093/alcalc/agq006

Source DB:  PubMed          Journal:  Alcohol Alcohol        ISSN: 0735-0414            Impact factor:   2.826


  6 in total

1.  Review of current clinical biomarkers for the detection of alcohol dependence.

Authors:  Hamid R Tavakoli; Michael Hull; Lt Michael Okasinski
Journal:  Innov Clin Neurosci       Date:  2011-03

2.  Biomarker testing to estimate under-reported heavy alcohol consumption by persons with HIV initiating ART in Uganda.

Authors:  Judith A Hahn; Mwebesa B Bwana; Martin A Javors; Jeffrey N Martin; Nneka I Emenyonu; David R Bangsberg
Journal:  AIDS Behav       Date:  2010-12

3.  Screening for alcohol and drug use disorders among adults in primary care: a review.

Authors:  Daniel J Pilowsky; Li-Tzy Wu
Journal:  Subst Abuse Rehabil       Date:  2012-04

Review 4.  Biomolecules and Biomarkers Used in Diagnosis of Alcohol Drinking and in Monitoring Therapeutic Interventions.

Authors:  Radu M Nanau; Manuela G Neuman
Journal:  Biomolecules       Date:  2015-06-29

5.  Carbohydrate-Deficient Transferrin as a Biomarker for Screening At-Risk Drinking in Elderly Men.

Authors:  Kwangmi Youn; Jong Sung Kim; Sung-Soo Kim; Seok Joon Yoon; Dong-Jin Woo
Journal:  Korean J Fam Med       Date:  2017-09-22

6.  A Comparison of the Predictive Power of DNA Methylation with Carbohydrate Deficient Transferrin for Heavy Alcohol Consumption.

Authors:  Shelly Miller; James A Mills; Jeffrey Long; Robert Philibert
Journal:  Epigenetics       Date:  2020-10-26       Impact factor: 4.528

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.